PMID- 25427165
OWN - NLM
STAT- MEDLINE
DCOM- 20160427
LR  - 20150707
IS  - 1534-6080 (Electronic)
IS  - 0041-1337 (Linking)
VI  - 99
IP  - 7
DP  - 2015 Jul
TI  - KIR and Human Leukocyte Antigen Genotype Associated Risk of Cytomegalovirus 
      Disease in Renal Transplant Patients.
PG  - 1506-13
LID - 10.1097/TP.0000000000000497 [doi]
AB  - BACKGROUND: Cytomegalovirus(CMV) infections have a significant effect on 
      morbidity and mortality in kidney transplants. We conducted a study to ascertain 
      the association of natural killer cell killer immunoglobulin-like receptors and 
      human leukocyte antigen (HLA) genotype with risk of CMV disease. METHODS: The 90 
      CMV-negative patients receiving a first renal transplantation from a CMV-positive 
      donor in this study received triple immunosuppressive therapy and prophylactic 
      CMV treatment for up to 3 months after transplantation. RESULTS: We observed a 
      43.3% incidence rate of CMV disease within the first year after transplantation. 
      Twenty-seven recipients experienced a rejection episode, 14 of which had CMV 
      disease, mostly after rejection, suggesting that in this group, CMV disease is 
      not a risk factor for rejection. KIR gene or genotype distribution were similar 
      between the CMV diseased and CMV disease-free group. Twenty-seven recipients 
      (30%) carried KIR-AA genotype, of which nine (33%) had CMV disease. Of the 
      remaining 63 (70%) recipients with KIR-BX genotype, 30 (48%) had CMV disease. 
      There was no significant difference between the two genotype groups with regard 
      to occurrence of CMV disease, although there was a trend toward a lower incidence 
      of CMV disease in recipients carrying the KIR-AA genotype. For CMV disease, we 
      found no significant risk associated with the number of activating or inhibitory 
      KIRs. Neither was missing KIR ligands for the inhibitory KIRs (HLA-C1/C2/Bw4) in 
      recipients associated with lower rates of CMV disease. CONCLUSION: In 
      CMV-negative recipients, genotypic analysis of KIR repertoire and HLA ligands 
      does not provide risk factors for primary CMV disease after renal 
      transplantation.
FAU - Michelo, Clive M
AU  - Michelo CM
AD  - 1 Department of Laboratory Medicine, Laboratory of Medical Immunology, Radboud 
      University Medical Center, Nijmegen, the Netherlands. 2 Department of Medical 
      Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands. 3 
      Department of Nephrology, Radboud University Medical Center, Nijmegen, the 
      Netherlands.
FAU - van der Meer, Arnold
AU  - van der Meer A
FAU - Tijssen, Henk J
AU  - Tijssen HJ
FAU - Zomer, Ramona
AU  - Zomer R
FAU - Stelma, Foekje
AU  - Stelma F
FAU - Hilbrands, Luuk B
AU  - Hilbrands LB
FAU - Joosten, Irma
AU  - Joosten I
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Transplantation
JT  - Transplantation
JID - 0132144
RN  - 0 (Antiviral Agents)
RN  - 0 (HLA Antigens)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Receptors, KIR)
SB  - IM
MH  - Adult
MH  - Antiviral Agents/administration & dosage
MH  - Cytomegalovirus Infections/epidemiology/*genetics/immunology/prevention & 
      control/virology
MH  - Drug Therapy, Combination
MH  - Female
MH  - Gene Frequency
MH  - Genetic Predisposition to Disease
MH  - Graft Rejection/epidemiology/genetics/immunology
MH  - HLA Antigens/*genetics/immunology
MH  - Humans
MH  - Immunocompromised Host
MH  - Immunosuppressive Agents/adverse effects
MH  - Incidence
MH  - Kidney Transplantation/*adverse effects
MH  - Male
MH  - Middle Aged
MH  - Phenotype
MH  - Receptors, KIR/*genetics/immunology
MH  - Risk Factors
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2014/11/27 06:00
MHDA- 2016/04/28 06:00
CRDT- 2014/11/27 06:00
PHST- 2014/11/27 06:00 [entrez]
PHST- 2014/11/27 06:00 [pubmed]
PHST- 2016/04/28 06:00 [medline]
AID - 10.1097/TP.0000000000000497 [doi]
PST - ppublish
SO  - Transplantation. 2015 Jul;99(7):1506-13. doi: 10.1097/TP.0000000000000497.